0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Gallium Nitrate for Advanced Paget Disease of Bone: Effectiveness and Dose-Response Analysis

Raymond P. Warrell Jr., MD; Barbara Bosco, RN; Stuart Weinerman, MD; Barbara Levine, PhD; Joseph Lane, MD; and Richard S. Bockman, MD, PhD
[+] Article and Author Information

Drs. Warrell and Bockman are co-patent holders on certain uses of gallium nitrate whose rights have been fully assigned to the Memorial Sloan-Kettering Cancer Center and licensed to Fujisawa Pharmaceutical Company. Drs. Warrell and Bockman have both subsequently acted as consultants to the company, and the company provided financial support to both Memorial Sloan-Kettering Cancer Center and the Hospital for Special Surgery to cover costs of the study.

Grant Support: By grants CA-42445 and CA-38645 from the National Cancer Institute, DHHS; and by a grant from Fujisawa Pharmaceutical Company, Deerfield, Illinois.

Requests for Reprints: Dr. Raymond P. Warrell, Jr., MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Current Author Addresses: Dr. Warrell: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Drs. Weinerman, Levine, Lane, Bockman, and Ms. Bosco: Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021.


© 1990 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1990;113(11):847-851. doi:10.7326/0003-4819-113-11-847
Text Size: A A A

Objective: To evaluate whether a brief course of treatment with gallium nitrate can reduce biochemical parameters of accelerated bone turnover in patients with advanced Paget disease.

Design: Unblinded trial, decreasing dose schedules of gallium nitrate.

Setting: University hospital with primary orthopedic and metabolic bone disease specialty.

Patients: Ten patients with advanced Paget disease who had previously received conventional therapy consisting of calcitonin, etidronate, or mithramycin.

Interventions: Five patients were entered into each of three dose schedules: 2. 5 mg/kg body weight per day by continuous intravenous infusion for 7 days; 0.5 mg/kg per day for 14 days by subcutaneous injection; and 0.25 mg/kg per day for 14 days by subcutaneous injection. Several patients were treated with different dose schedules. Patients were followed until relapse.

Results: Fifteen courses of treatment were administered to ten patients. Reductions in serum alkaline phosphatase and urinary hydroxyproline excretion were observed after treatment with each dose schedule. After treatment with high, intermediate, and low doses, the median maximum decreases in serum alkaline phosphatase activity were 49%, 39%, and 18%, respectively. The median maximum decreases in urinary hydroxyproline excretion were 50%, 52%, and 16%, respectively. The maximum decrease in urinary hydroxyproline excretion occurred within a median of 2 weeks from the start of treatment, whereas the maximum decrease in serum alkaline phosphatase activity occurred substantially later at a median of 6 weeks. All treatment schedules were well tolerated. Response duration was highly variable (range, 6 to 42 weeks).

Conclusions: Short-term treatment with gallium nitrate can reduce biochemical parameters of disease activity in patients with advanced Paget disease of bone. Larger trials using low-dose intermittent treatment schedules are required to evaluate the safety and effectiveness of this therapy.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Paget's disease of the spine and its management. Eur Spine J 2001;10(5):370-84.
The effects of gallium nitrate on bone resorption. Semin Oncol 2003;30(2 Suppl 5):5-12.

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)